GlassScriptPhysician profile
Amrit Paudel
NPI 1083080113
$2,777.72
in general payments reported to CMS, 2019-2025
19 companies · $2,298 in 2025
The $2,298 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $127 · 2024: $353 · 2025: $2,298.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,382 · Education: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,381.80 |
| Education | $395.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $395.92 | 2025 | |
| Janssen Biotech, INC. | $348.32 | 2025 | Tecvayli, Darzalex, Rybrevant |
| Glaxosmithkline, LLC. | $227.50 | 2024-2025 | Ojjaara |
| Amgen INC. | $223.55 | 2023-2025 | Blincyto, Nplate |
| Beone Medicines USA, INC. | $211.03 | 2025 | Tevimbra |
| Daiichi Sankyo INC. | $174.75 | 2024-2025 | Datroway, Enhertu |
| Astrazeneca Pharmaceuticals LP | $173.79 | 2025 | Enhertu |
| Janssen Scientific Affairs, LLC | $165.41 | 2024-2025 | Rybrevant, Darzalex, Carvykti |
| Gilead Sciences, INC. | $163.39 | 2025 | Trodelvy |
| Adaptive Biotechnologies Corporation | $134.73 | 2024-2025 | Clonoseq |
| Novocure INC. | $123.44 | 2025 | Optune Lua (Novottf-200t) |
| Genentech USA, INC. | $92.18 | 2025 | |
| Pfizer INC. | $73.92 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $71.80 | 2025 | |
| Springworks Therapeutics, INC. | $68.79 | 2025 | Ogsiveo, Gomekli |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $37.04 | 2025 | Libtayo |
| Genzyme Corporation | $34.23 | 2025 | |
| Caris Mpi, INC. | $30.94 | 2025 | Mi Cancer Seek |
| Kite Pharma, INC. | $26.99 | 2023 | Yescarta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrit Paudel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.